May 9
|
Takeda Pharmaceutical Projects Lower Annual Profit After Quarterly Loss
|
May 9
|
Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
|
May 8
|
Protagonist Therapeutics Inc (PTGX) Surpasses Q1 Revenue Estimates with Strategic Collaborations
|
Apr 29
|
Down -6.19% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
|
Apr 26
|
Down -5.9% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
|
Apr 26
|
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
|
Apr 26
|
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
|
Apr 25
|
All You Need to Know About Takeda Pharmaceutical Co. (TAK) Rating Upgrade to Strong Buy
|
Apr 25
|
TAK or CTLT: Which Is the Better Value Stock Right Now?
|
Apr 25
|
20 Fastest Growing Health Tech Companies in the World
|
Apr 25
|
New Strong Buy Stocks for April 25th
|
Apr 25
|
Best Value Stocks to Buy for April 25th
|
Apr 25
|
Best Income Stocks to Buy for April 25th
|
Apr 23
|
Takeda Pharmaceutical: A Long-Term Cash Cow
|
Apr 23
|
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
|
Apr 22
|
Pharmas form joint venture to jumpstart Japanese drug research
|
Apr 22
|
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
|
Apr 19
|
MasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors
|
Apr 18
|
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
|
Apr 8
|
Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food
|